ContraVir Pharma

CTRV NASDAQ
0.1165
-0.0047
-3.88%
After Hours: 0.1185 +0.002 +1.72% 16:42 05/17 EDT
Open
0.1270
Prev Close
0.1212
High
0.1270
Low
0.1150
Volume
1.97M
Avg Vol (3M)
2.92M
52 Week High
2.600
52 Week Low
0.1000
% Turnover
5.71%
Market Cap
4.01M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers ContraVir Pharma CTRV stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

ContraVir Pharmaceuticals, Inc. is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver high intrahepatic concentrations of TFV while minimizing off target effects caused by high levels of circulating TFV, and has completed a Phase IIa trial. CRV431, the other anti-HBV compound, is a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg).
MORE >

Recently

Name
Price
%Change